ZA200704236B - An oral preparation having improved bioavailability - Google Patents

An oral preparation having improved bioavailability

Info

Publication number
ZA200704236B
ZA200704236B ZA200704236A ZA200704236A ZA200704236B ZA 200704236 B ZA200704236 B ZA 200704236B ZA 200704236 A ZA200704236 A ZA 200704236A ZA 200704236 A ZA200704236 A ZA 200704236A ZA 200704236 B ZA200704236 B ZA 200704236B
Authority
ZA
South Africa
Prior art keywords
oral preparation
improved bioavailability
compound
disclosed
bioavailability
Prior art date
Application number
ZA200704236A
Other languages
English (en)
Inventor
Ryu Jei Man
Cho Soon Ki
Jung Se Hyun
Seong Seung-Kyoo
Cho Eun Hee
Ahn Seok Hoon
Kim Yun-Jung
Original Assignee
Dong Wha Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36498212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200704236(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dong Wha Pharm Ind Co Ltd filed Critical Dong Wha Pharm Ind Co Ltd
Publication of ZA200704236B publication Critical patent/ZA200704236B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
ZA200704236A 2004-11-23 2007-05-24 An oral preparation having improved bioavailability ZA200704236B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20040096390 2004-11-23

Publications (1)

Publication Number Publication Date
ZA200704236B true ZA200704236B (en) 2008-11-26

Family

ID=36498212

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200700485A ZA200700485B (en) 2004-11-23 2007-01-17 N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy} benzamidine 2 methansulfonic acid salt
ZA200704236A ZA200704236B (en) 2004-11-23 2007-05-24 An oral preparation having improved bioavailability

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ZA200700485A ZA200700485B (en) 2004-11-23 2007-01-17 N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy} benzamidine 2 methansulfonic acid salt

Country Status (19)

Country Link
US (2) US20070254930A1 (xx)
EP (2) EP1701722B1 (xx)
JP (2) JP4774053B2 (xx)
KR (2) KR100716389B1 (xx)
CN (3) CN101693029B (xx)
AT (1) ATE445397T1 (xx)
AU (2) AU2005300239B2 (xx)
BR (2) BRPI0517396A (xx)
CA (2) CA2552766C (xx)
DE (1) DE602005017118D1 (xx)
DK (1) DK1701722T3 (xx)
ES (1) ES2333739T3 (xx)
HK (1) HK1094530A1 (xx)
IL (2) IL180985A (xx)
NZ (1) NZ555725A (xx)
PT (1) PT1701722E (xx)
RU (1) RU2361867C2 (xx)
WO (2) WO2006057507A1 (xx)
ZA (2) ZA200700485B (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1773333A4 (en) * 2004-07-05 2010-04-21 Dong Wha Pharm Co Ltd COMPOSITION FOR THE PREVENTION AND TREATMENT OF ALLERGIC INFLAMMATORY DISEASES
KR20060017929A (ko) * 2004-08-04 2006-02-28 동화약품공업주식회사 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물
WO2006057507A1 (en) * 2004-11-23 2006-06-01 Dong Wha Pharm.Ind.Co., Ltd An oral preparation having improved bioavailability
ATE494282T1 (de) * 2007-04-19 2011-01-15 Dong Wha Pharm Co Ltd 2-ethansulfonsäuresalz aus n- hydroxy-4-ä5-ä4-(5- isopropyl-2-methyl-1,3-thiazol-4- yl)phenoxyüpentoxyü benzamidin, verfahren zu seiner herstellung und pharmazeutische zusammensetzung damit
JP5656258B2 (ja) * 2011-03-09 2015-01-21 塩野義製薬株式会社 ガランタミンを含有する口腔内崩壊錠剤
ES2841809T3 (es) 2011-06-03 2021-07-09 Eisai R&D Man Co Ltd Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
JP6292744B2 (ja) * 2012-09-19 2018-03-14 富士カプセル株式会社 医薬品組成物
JP6379044B2 (ja) * 2013-01-31 2018-08-22 沢井製薬株式会社 テルミサルタンとヒドロクロロチアジドとを含有する多層錠剤
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
HUE064614T2 (hu) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Eljárás egy kinolin-származék keserû ízének elnyomására
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
WO2016175230A1 (ja) 2015-04-28 2016-11-03 アステラス製薬株式会社 経口投与用医薬組成物
AU2016279474B2 (en) 2015-06-16 2021-09-09 Eisai R&D Management Co., Ltd. Anticancer agent
SG11202001436YA (en) * 2017-08-18 2020-03-30 Abbvie Inc Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
KR102276547B1 (ko) * 2020-09-04 2021-07-13 주식회사유한양행 오메프라졸, 에스오메프라졸 또는 이의 약제학적으로 허용가능한 염을 포함하는 정제 형태의 약학 조성물 및 이의 제조방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
EP0379579A4 (en) * 1988-02-03 1991-01-02 Yoshitomi Pharmaceutical Industries, Ltd. Pharmaceutical composition having improved releasability
PA8441701A1 (es) * 1996-11-26 2000-05-24 Pfizer Sales dimesilato de los ligandos del neuropeptido y
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
AU776193B2 (en) * 1999-10-28 2004-09-02 Sankyo Company Limited Benzamidine derivatives
KR100454767B1 (ko) * 2001-07-19 2004-11-03 동화약품공업주식회사 4-[(4-티아졸릴)페녹시]알콕시-벤즈아미딘 유도체의골다공증 예방 및 치료제로서의 용도
KR100789567B1 (ko) * 2001-11-06 2007-12-28 동화약품공업주식회사 3-아미도-1,2-벤조이소옥사졸 유도체, 그 염, 제조방법 및 용도
DK1490024T3 (da) * 2002-03-06 2012-04-10 Effrx Pharmaceuticals Sa Alendronatholdige brusesammensætninger
MXPA04009960A (es) * 2002-04-12 2004-12-13 Pfizer Compuestos de pirazol como agentes anti-inflamatorios y analgesicos.
WO2003101431A1 (en) * 2002-06-04 2003-12-11 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
KR101173580B1 (ko) * 2003-03-18 2012-08-13 코와 가부시키가이샤 제산제 조성물
WO2006057507A1 (en) * 2004-11-23 2006-06-01 Dong Wha Pharm.Ind.Co., Ltd An oral preparation having improved bioavailability

Also Published As

Publication number Publication date
CN101693029A (zh) 2010-04-14
AU2005300239B2 (en) 2009-08-06
BRPI0514386A (pt) 2008-06-10
CA2552766C (en) 2010-08-17
ATE445397T1 (de) 2009-10-15
KR20060057511A (ko) 2006-05-26
AU2005307994A1 (en) 2006-06-01
EP1701722A4 (en) 2007-05-16
DE602005017118D1 (de) 2009-11-26
IL182647A0 (en) 2007-07-24
ES2333739T3 (es) 2010-02-26
WO2006057507A1 (en) 2006-06-01
US20090176846A1 (en) 2009-07-09
EP1701722B1 (en) 2009-10-14
CN101056658A (zh) 2007-10-17
WO2006057501A1 (en) 2006-06-01
RU2007123614A (ru) 2008-12-27
KR20060057514A (ko) 2006-05-26
CA2585003C (en) 2010-08-17
JP2008508264A (ja) 2008-03-21
BRPI0514386B1 (pt) 2021-02-09
CN1905871A (zh) 2007-01-31
CN101693029B (zh) 2011-11-02
BRPI0514386B8 (pt) 2021-05-25
KR101047042B1 (ko) 2011-07-06
BRPI0517396A (pt) 2008-10-14
PT1701722E (pt) 2009-12-10
CN100574756C (zh) 2009-12-30
AU2005307994B2 (en) 2009-07-23
CN1905871B (zh) 2010-07-07
US20070254930A1 (en) 2007-11-01
CA2585003A1 (en) 2006-06-01
ZA200700485B (en) 2007-11-28
EP1701722A1 (en) 2006-09-20
IL180985A (en) 2012-02-29
JP4773456B2 (ja) 2011-09-14
HK1094530A1 (en) 2007-04-04
JP2008520655A (ja) 2008-06-19
EP1814593A4 (en) 2012-09-05
KR100716389B1 (ko) 2007-05-11
DK1701722T3 (da) 2010-01-11
CA2552766A1 (en) 2006-06-01
RU2361867C2 (ru) 2009-07-20
JP4774053B2 (ja) 2011-09-14
IL182647A (en) 2011-04-28
AU2005300239A1 (en) 2006-07-06
NZ555725A (en) 2008-07-31
IL180985A0 (en) 2007-07-04
EP1814593A1 (en) 2007-08-08

Similar Documents

Publication Publication Date Title
IL182647A0 (en) An oral preparation having improved bioavailability
CY1107238T1 (el) Παρασκευη μιας πολυμορφικης μορφης ενος παραγωγου θειαζολιδινοδιονης
WO2007009656A3 (de) Neues 1,4-benzothiazepin-1,1-dioxidderivat mit verbesserten eigenschaften, verfahren zu dessen herstellung, diese verbindung enthaltende arzneimittel und dessen verwendung
WO2003097622A3 (en) Synthesis of 2-alkylcysteines, 2-(hydroxylated phenyl)-4-alkylthiazoline-4-carboxylic acids and derivatives thereof
WO2009025983A3 (en) Method for preparing 5-haloalkyl-4,5-dihydroisoxazole derivatives
WO2008126899A1 (ja) ５員環へテロ環誘導体及びその医薬用途
WO2006067103A3 (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
WO2011141933A3 (en) Process for preparation of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid and its pharmaceutically acceptable salts
UA92354C2 (xx) Амінокислі солі росиглітазону$аминокислые соли росиглитазона
EP1078923A3 (en) Process for the preparation of benzothiophene derivatives
WO2006003471A3 (en) Process for the preparation of pramipexole by chiral chromatography
WO2007057225A3 (en) Process for making montelukast and intermediates therefor
UA90304C2 (xx) Сіль безилату 7-(2-(4-(3-трифторметилфеніл)-1,2,3,6-тетрагідропірид-1-ил)етил)ізохіноліну, її одержання і застосування в терапії$соль безилата 7-(2-(4-(3-трифторметилфенил)-1,2,3,6-тетрагидропирид-1-ил)этил)изохинолина, ее получение и применение в терапии
CA2454022A1 (en) Use of 4-[(4-thiazolyl)phenoxy]alkoxy-benzamidine derivatives for treatment of osteoporosis
WO2008133128A1 (ja) 縮合複素環誘導体、それを含有する医薬組成物及びその医薬用途
NO20063111L (no) Fremgangsmate for fremstilling av tiazolpyrimidiner
WO2007133481A3 (en) Method for increasing the bioavailability of benzhydryl piperazine containing compounds
GB0410013D0 (en) Process
WO2002072567A3 (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
EP2146974A4 (en) SALT OF N-HYDROXY-4- {5- [4- (5-ISOPROPYL-2-METHYL-1,3-THIAZOL-4-YL) PHENOXY] PENTOXY} BENZAMIDINE 2-ETHANESULPHONIC ACID, ITS PREPARATION METHOD AND COMPOSITION PHARMACEUTICAL COMPRISING IT
WO2005012273A3 (en) Process for the preparation of substituted thiazoles
AU2003269483A1 (en) Phosphoric acid salt of 5-((4-(2-(methyl-2-pyridinylamino) ethoxy) phenyl) methyl)- 2,4-thiazolidinedione
WO2005021542A3 (en) Process for the preparation of pioglitazone
EP1403260A3 (en) Optically active epoxy compounds and processes for their production
WO2006021654A8 (fr) Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique